Free Trial
NASDAQ:PROK

ProKidney (PROK) Stock Price, News & Analysis

ProKidney logo
$1.65 -0.15 (-8.33%)
(As of 11/20/2024 ET)

About ProKidney Stock (NASDAQ:PROK)

Key Stats

Today's Range
$1.62
$1.81
50-Day Range
$1.55
$2.46
52-Week Range
$1.18
$4.44
Volume
329,693 shs
Average Volume
445,666 shs
Market Capitalization
$477.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Consensus Rating
Hold

Company Overview

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

ProKidney Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
52nd Percentile Overall Score

PROK MarketRank™: 

ProKidney scored higher than 52% of companies evaluated by MarketBeat, and ranked 587th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ProKidney has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    ProKidney has only been the subject of 3 research reports in the past 90 days.

  • Read more about ProKidney's stock forecast and price target.
  • Earnings Growth

    Earnings for ProKidney are expected to grow in the coming year, from ($0.54) to ($0.44) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ProKidney is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ProKidney is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about ProKidney's valuation and earnings.
  • Percentage of Shares Shorted

    13.64% of the float of ProKidney has been sold short.
  • Short Interest Ratio / Days to Cover

    ProKidney has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in ProKidney has recently decreased by 3.72%, indicating that investor sentiment is improving.
  • Dividend Yield

    ProKidney does not currently pay a dividend.

  • Dividend Growth

    ProKidney does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.64% of the float of ProKidney has been sold short.
  • Short Interest Ratio / Days to Cover

    ProKidney has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in ProKidney has recently decreased by 3.72%, indicating that investor sentiment is improving.
  • News Sentiment

    ProKidney has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for ProKidney this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for PROK on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ProKidney insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,030.00 in company stock.

  • Percentage Held by Insiders

    41.49% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ProKidney's insider trading history.
Receive PROK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter.

PROK Stock News Headlines

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Pharma company to expand Broward headquarters
ProKidney’s Progress in FDA Approval and Financial Health
See More Headlines

PROK Stock Analysis - Frequently Asked Questions

ProKidney's stock was trading at $1.78 at the beginning of 2024. Since then, PROK stock has decreased by 7.3% and is now trading at $1.65.
View the best growth stocks for 2024 here
.

ProKidney Corp. (NASDAQ:PROK) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.14) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.14).

Top institutional shareholders of ProKidney include Suvretta Capital Management LLC (4.26%), Geode Capital Management LLC (0.76%), State Street Corp (0.49%) and Charles Schwab Investment Management Inc. (0.26%). Insiders that own company stock include Control Empresarial De Capital and Darin J Weber.
View institutional ownership trends
.

Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that ProKidney investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Tesla (TSLA).

Company Calendar

Last Earnings
11/12/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/20/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PROK
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.50
High Stock Price Target
$6.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+172.7%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-35,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($4.84) per share

Miscellaneous

Free Float
169,489,000
Market Cap
$477.96 million
Optionable
Optionable
Beta
1.11
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:PROK) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners